Legal Representation
Attorney
Diane B. Melnick
USPTO Deadlines
Next Deadline
1262 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20230606)
Due Date
June 06, 2029
Grace Period Ends
December 06, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
31 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 1, 2024 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Sep 6, 2024 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Oct 3, 2023 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Sep 7, 2023 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Sep 7, 2023 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Sep 6, 2023 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Jun 6, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Jun 6, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jun 5, 2023 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | Loading... |
| May 17, 2023 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| May 17, 2023 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | Loading... |
| Mar 21, 2023 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| Mar 21, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 21, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 1, 2023 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Mar 1, 2023 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Mar 1, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 14, 2023 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Feb 6, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 5, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 5, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Feb 5, 2023 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Aug 29, 2022 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Aug 11, 2022 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Aug 11, 2022 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Jul 21, 2022 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Jul 20, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jul 19, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Dec 24, 2021 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Dec 20, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Dec 16, 2021 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 042
Scientific research; pharmaceutical research; medical research services in the field of medicines; technical advice for third parties in the field of development of pharmaceutical products; product development for third parties in the field of pharmaceutical products; research and development of pharmaceuticals and medicinal preparations and substances for third parties; research and development of pharmaceuticals and medicinal preparations and substances for the treatment of cancer; research and development of pharmaceuticals and medicinal preparations and substances for treating inflammation; research and development of pharmaceuticals and medicinal preparations and substances for the treatment of neurodegenerative disorders; research and development of pharmaceutical and medicinal preparations and substances for the treatment of metabolic disorders; research and development of pharmaceutical and medicinal preparations and substances for the treatment of musculoskeletal disorders; research and development of pharmaceutical and medicinal preparations and substances for the treatment of osteoarthritis; research and development of pharmaceutical and medicinal preparations and substances for the treatment of genetic disorders and rare diseases
Classification
International Classes
042